In this study, Iso was shown to be effective in ameliorating CDDP-induced AKI via the SIRT1/SIRT6-Nrf2 pathway, indicating that Iso may be a novel and promising therapeutic agent. This evidence concerns the gene SIRT6 and acute kidney injury.